Analysts: Baidu’s Growth is Declining and 4 New Opinions Investors Must Take a Peek At

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Biogen Idec Inc. (NASDAQ:BIIB): Stifel decided to raise the company’s price target due to its belief that the label assigned by the FDA to the company’s MS drug, Tecfidera, was more favorable than expected. The firm is convinced that the label de-risks its estimates, and it keeps its Buy rating on the stock. The company’s price target was increased by Brean Capital after the FDA approval of Tecfidera labeling, which removes an overhang and indicates that consensus revenue guidance of $330 million is possilbe. The firm gives the shares a Buy rating.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

BIIB

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business